Bluebird Bio (BLUE, Financial) stock experienced a notable surge of 5.04% to $0.494 per share. The trading volume reached 6.47552 million shares, resulting in a turnover rate of 3.34% and a volatility of 8.69%.
According to the latest financial report, Bluebird Bio posted a revenue of $16.10 million, a net loss of $81.39 million, an earnings per share (EPS) of -$0.42, and a gross profit of -$12.85 million. The company's price-to-earnings (P/E) ratio stands at -0.21.
Among the ten institutions that rated the stock, 30% recommended buying, 60% suggested holding, and 10% advised selling.
The biotechnology sector, where Bluebird Bio operates, saw an overall decline of 0.99%. Within this sector, Tc Biopharm (Holdings) Plc C/Wts 10/02/2028 (To Pur Ads), Bioatla, Inc., and Coeptis Therapeutics Holdings Inc C/Wts 31/12/2024 (To Pur Com) showed significant gains. Active stocks included Aditxt, Inc., Windtree Therapeutics, Inc., and Tc Biopharm (Holdings) Plc, with turnover rates of 1254.09%, 70.30%, and 58.00% respectively. High volatility was noted in Pasithea Therapeutics Corp C/Wts 12/08/2026 (To Pur Com), Tevogen Bio Holdings Inc C/Wts 14/02/2029 (To Pur Com), and Apollomics Inc C/Wts 01/04/2028 (To Pur Ord) with volatilities of 145.55%, 70.19%, and 60.44% respectively.
Bluebird Bio Inc is a biotechnology company focused on developing potentially curative gene therapies for severe genetic diseases using its proprietary lentiviral vector (LVV) gene addition platform.
